Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors : Episode 4
Opinion
Video
Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors
Author(s):
Key Takeaways
- Combining BCG and PD-1/PD-L1 inhibitors may enhance antitumor activity through complementary mechanisms, potentially improving outcomes in NMIBC.
- BCG stimulates immune response, while PD-1/PD-L1 inhibitors prevent immune evasion, providing a rationale for their combined use.
EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging
EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC
Now Viewing
EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors
Video content above is prompted by the following:
- How might the combination of BCG and PD-1/PD-L1 inhibitors affect antitumor activity compared with using each agent alone?
- What is the rationale for using these therapies in combination?
- How do you think the combination therapies will evolve treatment of non–muscle-invasive bladder cancer (NMIBC)?
- How would the use of PD-1/PD-L1 inhibitors plus BCG in high-risk NMIBC impact patient flow in urology practice?
THE SPEAKER WILL HIGHLIGHT THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH
Related Videos
Related Content
